Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the update, but either way it is in his best interest to maximize value.
Granted I am just an ignorant drunk backwoods redneck. But if I were in his shoes I would sell the company in 3 years after the shares are vested.
The rules have definitely changed with the lame Up Tick Rule that we now have in place. IMO it makes historical analysis of the stock market somewhat irrelevant in biotech unless you use July 6, 2007; as your starting point.
Not grinning about the cost. I am demented, but not that demented. Skol.
Saw headline in USA Today about estimated $1 million cost for CAR-T. Up in Green Bay this week grinning from ear to ear.
Thank you for your service to our Great Country; I have the upmost respect for our Vietnam Vets!
Yeah I hear you on that; only good thing is buying opportunity. Hopefully we can purge ourselves of these parasites that you describe.
Also recent patent possibly addressing parasites?
http://ir.advaxis.com/press-releases/detail/1197/advaxis-expands-intellectual-property-for-lm-technology
Interesting that some estimates of 1/3 of world's population possibly affected by parasites:
http://cmr.asm.org/content/25/4/585.full
Something that must possibly be addressed for vaccine efficacy. I thought I remember reading at one time possibly in old annual report that this was a potential problem with the trial in India? Not 100% sure how this potential problem is being addressed?
Thank you for your analysis! Infectious disease, influenza, allergies, infant vaccinations and FMD in cloven hoof animals are also potentially huge markets; but only speculative at this time as far as I know.
Thanks Iggy, I guess I see the value to someone else late to the party to pay $14 for ADXSW if the ADXS share price is $20. Not sure exactly how close ADXSW tracks to ADXS. I think FBG probably played this correctly when the warrants first came out, by converting shares to warrants and then selling the warrants during the run-up.
I get the part about trading ADXSW for a higher value. But at this point why would anyone want to convert to ADXS if it costs you an additional $5 on top of what you paid for the share of ADXSW? I just do not see the time/value with only a year left before the warrants are worthless? Am I not interpreting correctly that you have to fork out another $5 per ADXSW share to get the ADXS share? Or do I have the option to convert to ADXS for nothing once the ADXS share price is above $5?
Thanks, so $1.87 + $5 = $6.87 = one share of ADXS
I will stick to just buying regular shares of ADXS under $5
Quick question on the warrants. So the ADXSW share price has to be $5 or higher before October 17th, 2018 in order to convert one warrant into one share of ADXS? Otherwise they expire worthless?
Thanks, thinking about buying some.
Interesting link to LM stats in food and environment.
http://www.foodpoisonjournal.com/food-poisoning-resources/everything-you-never-wanted-to-know-about-listeria-but-need-to/
There are several strains of listeria; but my understanding is that only monocytogenes is a pathogen:
https://en.wikipedia.org/wiki/Listeria
Thanks James. Seems to be talking mostly about the very expensive CAR-T treatments. Glad that our vaccine is low cost and thus far has had a great safety profile. If Efficacy ends up being equal; one would speculate that low cost and safety will win out in the end.
Very true! Fortunately other kind folks on this board keep me updated with their great posts. This is truly a Great MB.
Any idea why the history of this trial shows "product_exported_from_us"?
Thanks Julius, that was about 80,000 beers ago so my memory is probably fading perhaps. Right before the clinical hold aye; was only one patient dosed or did the trial resurrect after the hold was lifted? Thanks
Interesting that this is about the time of the EU patent filing.
Hi Iggy, lots of talk; but never saw human dosing? Just my drunk backwoods take.
Trying to wrap my brain around the HER-2 EU patent that was filed last year?
http://ir.advaxis.com/press-releases/detail/1197/advaxis-expands-intellectual-property-for-lm-technology
More EU patent links:
http://ir.advaxis.com/press-releases/detail/1197/advaxis-expands-intellectual-property-for-lm-technology
http://content.stockpr.com/advaxis/news/2010-01-04_Advaxis_Awarded_European_Patent_for_New_Listeria_200.pdf
https://www.news-medical.net/news/20100104/EPO-approves-Advaxis-patent-application-for-Listeria-Antigens.aspx
http://content.equisolve.net/advaxis/news/2010-08-24_European_Patent_Office_Allows_Advaxis_U_Penn_70.pdf
http://ir.advaxis.com/press-releases/detail/132/advaxis-prevails-in-european-patent-court
EU Patents are good for 20 years I believe.
So potential partner needs to consider that we may have LM rights in EU to 2029?
EU patent coverage until 2029? or longer maybe?
http://patents.stackexchange.com/questions/12422/expiry-date-of-a-european-patent
Please let me know your take after you have had time to review these patents? Thanks
What you are implying may well be legit. But unless someone sold; it doesn't mean much. IMO the same folks that drug the SP down may well be the same ones that bring it up. Just look at the history of PBYI.
Dew, do these patents protect Dual, Hot and Neo for 10 years in US? Plus we own the EU, since ANZA (ADRO's predecessor) lost in court?
https://patents.justia.com/assignee/advaxis-inc
I have owned shares since this dropped to below 2 cents and below $3; and yes I regret not buying a $hit road at those levels. Does anyone know the difference between jelly and jam? Ron White explained it to me.
Also interesting that LM vaccine does not result in antibodies, so it can be given repeativly to improve results I believe? Also interesting that this summary orginated in Iran I believe?
Thanks for posting this article, noticed they were talking about possible shortcomings with the KBMA (killed but metabolically active); which I believe may have been ADRO's initial approach.
In my opinion the greatest strength of our platform is the ability to test, evaluate and change to make it better for future testing based on biomarkers and analysis. This beats the hell out of a treatment where you are stuck with one thing, and have limited options for change. IMO as the scientific knowledge advances, we adapt/change and get better.
Several of us long term shareholders, including FBG, have taken the ride below $3 a couple of times and it sucks. Hard to fathom going from below $3 to above $30 and back down to where we are now. I will admit to being a backwoods redneck novice, but a bunch of Neanderthals sitting around a fire trading shiny beads amongst themselves seems to make more sense then the stock market. Anyhow I have always believed in the science and am holding strong and embracing the suck.
10 million apologies if someone else has already posted this; but saw NCI grant for pancreatic study involving LM. Not sure if this is us or ADRO?
https://prevention.cancer.gov/research-groups/gastrointestinal-and-other-cancers/grants/R01CA184926
Small world, I am sure I have passed by your old place several times over the years. Both my grandparents and parents lived in Rockport from about 1976 to 2009. Sad to see the devastation wrought by Harvey. I saw where that old 7 - Eleven near the bridge got wiped out; back in the late seventies my cousin and I used to absolutely hammer the redfish and speck trout out in the coastal waters just past that place. Hope that both Blue and Barnie are safe in Florida. Take care!
Stay safe, we had a condo in our family at Key Allegro in Rockport, TX, that was sold about 7 years ago. I saw some recent pictures of it and the roof was completely torn off during Harvey.
I was surprised that the NEO trial did not include prostate cancer? I can only imagine the IP complexity of trying to license our constructs now that the crown jewel has already been given to Amgen?
Having trouble posting a link to this older prostate article; but it seems to me that all roads will probably lead to NEO or HOT possibly?:
https://prostate.org.nz/2015/04/scientists-reveal-genetic-root-of-prostate-cancer/
From www.health--insurance.me - November 26, 2016 9:42 AM
By James McIntosh
The research, published in Nature, is part of the International Cancer Genome Consortium - a global project committed to revealing genetic changes driving prostate cancer, using the most up-to-date gene-sequencing technology available.
Tumor samples from 10 men with prostate cancer were analyzed, allowing the researchers to map a "family tree" of changes occurring at a genetic level as the cancer develops.
The researchers also learned more about how the disease spreads through the body and forms new tumors. They discovered that the first group of cells that spread from the prostate continues to travel throughout the body, developing new tumors as it goes.
"We gained a much broader view of prostate cancer by studying both the original cancer and the cells that had spread to other parts of the body in these men," says study author Prof. Ros Eeles from the Institute of Cancer Reseach in London, UK. "And we found that all of the cells that had broken free shared a common ancestor cell in the prostate."
Prostate cancer is the second most common cancer in American men behind skin cancer and the second most common cause of cancer death behind lung cancer. Around 1 in 7 men will be diagnosed with prostate cancer during their lifetime.
According to American Cancer Society (ACS) estimates, in 2015, around 220,800 new cases of prostate cancer will be diagnosed, and 27,540 deaths will occur attributable to the disease.
The researchers have already discovered that cancer cells taken from different sites within a man's prostate can be very diverse genetically. Despite this, the new study found that cancer cells moving away from the prostate share genetic faults that are unique to the man whose cancer it is.
"The common faults we found in each man could potentially offer new targets for treatment," states Prof. Eeles. "But we found that, once cancer cells have spread, they continue to evolve genetically, so choosing the most effective treatments will remain a key challenge."
Shared mutations represent 'a potential Achilles heel' for prostate cancer Prof. Steven Bova from the University of Tampere in Finland believes that in order to find these shared genetic faults, multiple biopsies may be needed. "We must also study more patients to learn how to apply these findings to develop more personalized treatments for people with the disease," he adds.
Learning how cancer cells change and evolve as they metastasize (spread to other parts of the body) and thus become resistant to certain forms of treatment is crucial to developing future treatments for all forms of cancer.
Senior author Dr. Ultan McDermott says that while the shared tumor-causing genetic faults mapped by their "family tree" represent a potential Achilles heel for prostate cancer, "many of these shared mutations are in tumor suppressor genes and our approach to therapeutically targeting these needs to be prioritized."
"We have to zoom in on this crucial junction and gather more data on the impact different therapies have on prostate cancer's evolution and spread," he adds.
The study authors conclude that these findings "elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen-deprivation therapy in prostate cancer."
Recently, Medical News Today reported on new research suggesting that taking vitamin D supplements could slow or reverse the progression of low-grade prostate tumors, reducing the need for surgery or radiation therapy.
Godspeed to SP over $30; although that may not stop the $20 to $25 buyout predictions
Please start posting about a buyout at $31.01 or higher; otherwise my liver is f'd for all your 20 to 25 dollar buyout predictions, which I am doing a shot for everyone.
Agree, DNDN achieved a market cap of something like 6 Billion after their prostate drug approval. I speculate that our construct will be much less expensive and hopefully more effective.
I am behind on reading the board posts; so 1,000 apologies in advance if someone has already posted this study on chemo:
https://www.cancer.gov/news-events/cancer-currents-blog/2017/chemotherapy-effect-metastasis?cid=eb_govdel